Changing patterns in HIV reverse transcriptase resistance mutations after availability of tenofovir

Clin Infect Dis. 2008 Jun 1;46(11):1782-5. doi: 10.1086/588045.

Abstract

Assessment of 1177 human immunodeficiency virus (HIV) resistance genotypes at an HIV/AIDS clinic showed a decrease in the incidence of the K65R mutation, from 15.2% of isolates during the period 2002-2004 to 2.7% of isolates during the period 2005-2006 (P < .001), despite elevated and stable rates of tenofovir use. A reduction in the rate of coadministration of didanosine (from 41.6% of patients in 2004 to 0.8% of patients in 2006; P < .001) largely explained this observation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenine / analogs & derivatives
  • Adenine / pharmacology
  • Anti-HIV Agents / pharmacology*
  • Didanosine / pharmacology
  • Drug Resistance, Multiple, Viral / genetics*
  • HIV Infections / metabolism*
  • HIV Reverse Transcriptase / antagonists & inhibitors
  • HIV Reverse Transcriptase / genetics*
  • HIV-1 / drug effects
  • HIV-1 / enzymology
  • HIV-1 / genetics
  • Humans
  • Mutation
  • Organophosphonates / pharmacology
  • Retrospective Studies
  • Reverse Transcriptase Inhibitors / pharmacology*
  • Tenofovir

Substances

  • Anti-HIV Agents
  • Organophosphonates
  • Reverse Transcriptase Inhibitors
  • Tenofovir
  • HIV Reverse Transcriptase
  • Adenine
  • Didanosine